Drugs / ZT002
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07550816 | May → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06371326 | Nov 2023 → Apr 2024 | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06423872 | Jun → Oct 2023 | type 2 diabetes mellitus | Beijing QL Biopharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05491421 | Sep 2022 → Apr 2023 | type 2 diabetes mellitus | QL Biopharmaceutical Australia Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07065032 | Feb → Jul 2024 | type 2 diabetes mellitus | Beijing QL Biopharmaceutical Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZT002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07550816 ↗ |
| Modality | Peptide | “ZT002 is an ultralong-acting glucagon-like peptide-1.” NCT07550816 ↗ |
| Route | Subcutaneous | “single subcutaneous (SC) ZT002 dose” NCT05491421 ↗ |